The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes
- PMID: 9619693
- DOI: 10.1016/s0924-977x(97)00050-3
The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes
Abstract
The study of excitatory amino acids (EAAs) has recently resulted in new and fundamental concepts in neuroscience. This progress has led to a growing awareness of the crucial role that brain EAAs systems play in a variety of physiological and pathological processes. The N-methyl-D-aspartate (NMDA) receptor, presently the most well understood subtype of EAAs receptors, has been implicated in crucial physiological processes such as synaptogenesis, learning and memory. Dysfunctions of NMDA receptors seem to play a crucial role in the neurobiology of disorders such as Parkinson's disease, Alzheimer's disease, epilepsy and ischemic stroke. This paper is a review of emerging data indicating that alterations of NMDA receptor function may be pivotal to the pathophysiology of four common psychiatric syndromes: schizophrenia, major depression, posttraumatic stress disorder, and alcoholism. Special emphasis is placed on the current state of development of pharmacological strategies aiming at the modulation of NMDA receptor-mediated neurotransmission in these disorders.
Similar articles
-
Psychiatric drugs. Excited by glutamate.Science. 2003 Jun 20;300(5627):1866-8. doi: 10.1126/science.300.5627.1866. Science. 2003. PMID: 12817119 No abstract available.
-
NMDA neurotransmission as a critical mediator of borderline personality disorder.J Psychiatry Neurosci. 2007 Mar;32(2):103-15. J Psychiatry Neurosci. 2007. PMID: 17353939 Free PMC article. Review.
-
The role of glutamatergic neurotransmission in the pathophysiology of alcoholism.Annu Rev Med. 1998;49:173-84. doi: 10.1146/annurev.med.49.1.173. Annu Rev Med. 1998. PMID: 9509257 Review.
-
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders.Life Sci. 1996;58(9):721-34. doi: 10.1016/0024-3205(95)02248-1. Life Sci. 1996. PMID: 8632719 Review.
-
Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators.Neural Plast. 2017;2017:2875904. doi: 10.1155/2017/2875904. Epub 2017 Jan 9. Neural Plast. 2017. PMID: 28163934 Free PMC article. Review.
Cited by
-
The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive rats.Psychopharmacology (Berl). 2013 Mar;226(1):127-38. doi: 10.1007/s00213-012-2898-3. Epub 2012 Oct 27. Psychopharmacology (Berl). 2013. PMID: 23104264 Free PMC article.
-
Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus.Psychopharmacology (Berl). 2004 Oct;175(4):494-502. doi: 10.1007/s00213-004-1836-4. Psychopharmacology (Berl). 2004. PMID: 15138761
-
Polyunsaturated fatty acid supplementation for schizophrenia.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD001257. doi: 10.1002/14651858.CD001257.pub2. Cochrane Database Syst Rev. 2006. PMID: 16855961 Free PMC article.
-
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine.Neuropsychopharmacology. 2010 Feb;35(3):632-40. doi: 10.1038/npp.2009.168. Epub 2009 Nov 4. Neuropsychopharmacology. 2010. PMID: 19890262 Free PMC article. Clinical Trial.
-
Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging.Drugs Aging. 2001;18(10):717-24. doi: 10.2165/00002512-200118100-00001. Drugs Aging. 2001. PMID: 11735619 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical